Would Denmark’s Vaccine Policy Work in the US?

What’s going on:
The idea sounds deceptively simple. If Denmark vaccinates children against fewer diseases than the United States, and still manages strong public health outcomes, why not follow its lead?

That question has moved from academic debate into policy speculation after reports that Robert F. Kennedy Jr. could push for the US to mirror Denmark’s childhood vaccine schedule.

According to reporting from The New York Times, the proposal would shift the US away from its current slate of vaccines for roughly 18 diseases and toward Denmark’s leaner schedule, which covers about 10.

On paper, the contrast is striking. Denmark appears to do “more with less,” while the US operates one of the most expansive immunization programs in the world. But as public health experts are quick to note, the comparison is not straightforward. One epidemiologist summed it up bluntly: this is not apples to oranges. It is apples to steaks.

To understand why, it helps to look beyond the numbers and into the systems behind them.

How Denmark’s vaccine model actually works

Denmark is often held up as a model of streamlined public health. Its childhood vaccination program is centrally coordinated, universally accessible, and delivered through a tightly integrated healthcare system. Nearly all Danish children receive care through general practitioners who operate within a national framework, with consistent funding, data-sharing, and follow-up mechanisms.

The country itself is small (about 6 million people) and demographically more homogeneous than the United States. Geographic distances are shorter. Access points are predictable. Public trust in government health institutions remains relatively high. All of this matters.

When Denmark decides to add, remove, or modify a vaccine recommendation, it does so within a system designed to move in lockstep. Coverage does not depend on private insurers. Compliance does not vary widely by state. And messaging is not fragmented across dozens of agencies with competing political pressures.

This cohesion allows Denmark to run a tighter schedule without introducing significant gaps in population-level protection.

The US system is built differently by design

Now consider the US. Vaccine recommendations are developed through a science-driven, committee-led process involving the CDC, the Advisory Committee on Immunization Practices (ACIP), and layers of public review. The resulting schedule reflects not just disease risk, but population diversity, healthcare access disparities, and historical patterns of outbreaks.

The US population is roughly 55 times larger than Denmark’s. It spans vastly different climates, living conditions, and exposure risks. Urban density in New York does not resemble rural Montana. Childhood healthcare access in affluent suburbs does not mirror that in underserved communities.

In other words, the US vaccine schedule is not simply about protecting an “average” child. It is designed to protect the most vulnerable ones, across the widest range of circumstances.

That complexity is expensive. It is also intentional.

Why fewer vaccines doesn’t automatically mean better outcomes

Supporters of adopting Denmark’s model often point to strong health outcomes and high life expectancy. But those outcomes are not driven by vaccine schedules alone. They reflect a broader ecosystem: universal healthcare, paid parental leave, consistent preventive care, and lower baseline inequality.

Removing vaccines from the US schedule without replicating those structural supports would change the equation entirely.

There is also the issue of disease prevalence. Some illnesses remain rare in Denmark but circulate more readily in the US due to population density, international travel, and uneven vaccination coverage. Reducing protections in such an environment does not simply “match” Denmark’s risk profile. It reshapes it.

Public health experts warn that doing so could increase susceptibility to outbreaks that the current schedule is designed to prevent.

Insurance, access, and unintended consequences

What it means:
Even without an official decision, Politico reports that a planned announcement was scrapped last week; the implications are already raising concern among health policy analysts.

In the US, vaccine recommendations are closely tied to insurance coverage. Once a vaccine falls off the recommended schedule, insurers may no longer be required to cover it. That shift could leave families paying out of pocket or forgoing protection altogether.

There is more. Changing the schedule could also weaken legal protections for vaccine manufacturers, opening the door to increased litigation. Health experts warn this could disrupt supply chains, discourage innovation, and ultimately raise costs across the system.

Taken together, the ripple effects extend far beyond the question of “how many shots kids get.”

Trust, skepticism, and public perception

Vaccine policy does not operate in a vacuum. In the US, it exists within a charged cultural and political environment where trust in institutions varies widely. Any abrupt shift especially one framed as abandoning long-standing recommendations, risks fueling skepticism rather than reassurance.

Denmark benefits from relatively high institutional trust. When its health authorities adjust guidance, the public response is generally measured. In the US, similar changes can quickly become symbolic battlegrounds, interpreted as evidence of failure, overreach, or hidden motives.

Public health messaging relies on consistency. Reversals, even well-intentioned ones, carry reputational costs.

Could parts of the Danish approach translate?

None of this means the US cannot learn from Denmark. Streamlining delivery systems, improving follow-up care, and investing in centralized data infrastructure are all areas where American public health could improve. The lesson, however, is structural, not numerical.

Denmark’s success is not rooted in vaccinating against fewer diseases. It is rooted in how its healthcare system functions as a whole.

Trying to import one visible output a shorter vaccine list without the underlying machinery, is unlikely to deliver the same results.

Bottom Line

The appeal of Denmark’s vaccine policy lies in its simplicity. But simplicity in public health is often the product of complexity handled well, not complexity removed.

For parents, policymakers, and clinicians, the real question is not whether the US should vaccinate more or less. It is whether the system we have is capable of supporting any major change without introducing new risks.

Right now, experts say the answer is unclear.

And in public health, uncertainty is not a rounding error. It is a warning signal.